Showing results (61-70 of 95) with videos related to
Sort By:
Pageof 10
International Journal of Hematology|July 7, 2011
Clinical utility of the neutrophil distribution pattern obtained using the CELL-DYN SAPPHIRE hematology analyzer for the diagnosis of myelodysplastic syndromeTohru Inaba, Yoichi Yuki, Soichi Yuasa, et al.International Journal of Hematology|September 19, 2007
A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet responseTakayuki Ishikawa, Kaoru Tohyama, Shinji Nakao, et al.Biochemical and Biophysical Research Communications|February 22, 2012
Rab27b regulates c-kit expression by controlling the secretion of stem cell factorChisato Tanaka, Hiroaki Kaji, Jinsong He, et al.Cancer Research|June 15, 2017
β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q)Liping Li, Yue Sheng, Wenshu Li, et al.Cancer Science|July 29, 2025
TP-0903 Suppresses Aurora A-PLK1 Signaling to Inhibit Proliferation of a Myelodysplastic Syndrome-Derived Cell LineTomoko Kimura-Hyoda, Mikuri Ryu, Ryosuke Yuta, et al.Leukemia Research|June 14, 2003
Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in JapanTakashi Shimamoto, Kaoru Tohyama, Takahiro Okamoto, et al.Springerplus|August 10, 2016
Low neutrophil alkaline phosphatase score is a new aspect of calreticulin-mutated myeloproliferative neoplasmsToshinori Kondo, Taizo Tasaka, Nanako Tomioka, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|September 15, 2012
[Survey on examinations for diagnosis of bone marrow failure in Japan: a report from the Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes]Kayano Araseki, Akira Matsuda, Kaoru Tohyama, et al.Oncotarget|May 2, 2019
The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromesYuichi Murakami, Yoshizo Kimura, Akihiko Kawahara, et al.International Journal of Hematology|August 26, 2009
Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormalityHironori Harada, Mitsumasa Watanabe, Kenshi Suzuki, et al.Pageof 10